Fulgent Genetics Revenue Tops Estimates @themotleyfool #stocks $FLGT
2 Articles
2 Articles
Fulgent Genetics Revenue Tops Estimates @themotleyfool #stocks $FLGT
Laboratory services and therapeutic development specialist Fulgent Genetics (NASDAQ:FLGT) delivered a standout performance in the fourth quarter, topping analysts' consensus estimates. On Friday, Feb. 28, the company reported adjusted EPS of $0.04, outstripping expectations of a $0.12 per-share loss. Q4 revenue climbed to $76.2 million, exceeding estimates of $74 million, marking an impressive annual growth of 8.1%. Despite a GAAP earnings loss,…
Coverage Details
Bias Distribution
- 100% of the sources lean Left
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage